Faculty of Medicine, Zagazig University, Zagazig City, Sharkia 44519, Egypt; International Medical Research Association IMedRA, Egypt.
Faculty of Medicine, Zagazig University, Zagazig City, Sharkia 44519, Egypt; International Medical Research Association IMedRA, Egypt.
Med Clin (Barc). 2022 Jun 24;158(12):576-585. doi: 10.1016/j.medcli.2021.06.028. Epub 2021 Oct 17.
Type 2 diabetes mellitus (T2DM) is a progressive meta-inflammatory disorder, which induce micro and macrovascular complications. Resveratrol is a nutraceutical known to have antioxidant and anti-inflammatory properties. It improves insulin resistance; however, no clear evidence regarding its effects in patients with T2DM.
We aimed to evaluate the efficacy and the safety of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration.
We searched PubMed, Cochrane Library, Scopus, WOS, Wiley, and Google Scholar for RCTs evaluating the efficacy and safety of resveratrol on patients with T2DM. We screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies' characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3.
This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}, {MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=-0.41, 95%CI [-0.65, -0.16], P=0.001 and systolic blood pressure {MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}.
We concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.
2 型糖尿病（T2DM）是一种进行性的代谢炎症性疾病，可引起微血管和大血管并发症。白藜芦醇是一种具有抗氧化和抗炎特性的营养保健品。它可以改善胰岛素抵抗；然而，关于其在 T2DM 患者中的作用尚无明确证据。
我们旨在评估口服白藜芦醇补充剂在 2 型糖尿病患者中的疗效和安全性，具体涉及剂量和持续时间。
我们在 PubMed、Cochrane 图书馆、Scopus、WOS、Wiley 和 Google Scholar 上搜索了评估白藜芦醇对 T2DM 患者疗效和安全性的 RCTs。我们筛选了符合纳入标准的研究，进行了质量评估，提取了研究的特征、基线和感兴趣的结局数据，并最终使用 RevManV5.3 进行了荟萃分析。
本系统评价和荟萃分析纳入了 17 项 RCT，共纳入了 871 例 T2DM 患者，结果表明，白藜芦醇在 500mg 及以上剂量时，在空腹血糖（FBG）和总胆固醇（TC）方面优于安慰剂，{MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}，{MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001}。此外，它在三个月时改善了糖化血红蛋白（HbA1c），{MD=-0.41, 95%CI [-0.65, -0.16], P=0.001}和收缩压{MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}。
我们的结论是，白藜芦醇有益地调节了 T2DM 患者的血糖控制以及心脏代谢参数。
